Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4373474

N.O=C(O)c1ccc(Cl)cc1Cl

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.95
CASP1 P29466 1/20 0.95
SMN1; SMN2 Q16637 1/20 0.95
ALDH1A1 P00352 3/20 0.65
TP53 P04637 1/20 0.65
SRD5A2 P31213 1/20 0.61
MAPK1 P28482 1/20 0.59
HIF1A Q16665 1/20 0.59
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
KDM4E B2RXH2 1/20 0.57
MAPT P10636 1/20 0.57
ERCC5 P28715 1/20 0.56
FEN1 P39748 1/20 0.56
PPARG P37231 1/20 0.53
PPARA Q07869 1/20 0.53
AKR1C4 P17516 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
AKR1C1 Q04828 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111279 0.98 TSHR (1.00) TSHRCASP1SMN1; SMN2ALDH1A1TP53
SCHEMBL28852873 0.95 TSHR (0.95) TSHRCASP1SMN1; SMN2ALDH1A1TP53
SCHEMBL1303476 0.95 TSHR (0.95) TSHRCASP1SMN1; SMN2ALDH1A1TP53
SCHEMBL1151260 0.95 TSHR (0.95) TSHRCASP1SMN1; SMN2ALDH1A1TP53
Hydrochloric Acid SCHEMBL9651764 0.95 TSHR (0.95) TSHRCASP1SMN1; SMN2ALDH1A1TP53
SCHEMBL6233608 0.95 TSHR (0.95) TSHRCASP1SMN1; SMN2ALDH1A1TP53
Thioglycolic Acid SCHEMBL8860110 0.86 SMN1; SMN2 (0.78) TSHRCASP1SMN1; SMN2ALDH1A1TP53
Acetonitrile SCHEMBL28488651 0.86 TSHR (0.78) TSHRCASP1SMN1; SMN2ALDH1A1TP53
Benzoic Acid SCHEMBL8021112 0.86 TSHR (0.78) TSHRCASP1SMN1; SMN2ALDH1A1TP53
SCHEMBL8860105 0.85 SMN1; SMN2 (0.75) TSHRCASP1SMN1; SMN2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367824-B2 Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent UBE INDUSTRIES LTD. (JP) 2013-02-05 US disclosed
EP-1477481-B1 PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE UBE INDUSTRIES (JP) 2009-07-22 EP disclosed
US-20050080262-A1 Process for producing quinazolin-4-one derivative UBE INDUSTRIES, LTD. (JP) 2005-04-14 US disclosed
EP-1477481-A1 PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE Ube Industries, Ltd. (JP) 2004-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080262-A1 Process for producing quinazolin-4-one derivative NQO2, SDHA, CYP3A4 TSHR 2706/4885CASP1 1019/4885SMN1; SMN2 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.